[Infostock Daily = Reporter Kim Jong Hyo] GC Green Cross announced on the 29th that it applied for Phase 2 clinical trials IND(Investigational New Drug) of COVID-19 plasma treatment 'GC5131A' to the Ministry of Food and Drug Safety.
Through this clinical trial, it plan to set the appropriate dose of the drug and explore safety and efficacy. Clinical trials will be conducted at five hospitals including Samsung Seoul Hospital, Seoul Asan Hospital, Chungang University Hospital, Korea University Ansan Hospital and Chungnam National University Hospital.
'GC5131A' is a hyperimmune globulin made by extracting various effective immunobodies from plasma(liquid components of blood) in patients with COVID-19 recovery. This Hyperimmune globulin is a formulation that has been used in the human body for a long time, so the development process can be simplified.
In fact, 'GC5131A' is the fastest to enter Phase 2 clinical trials except for drug re-creation products.
Reporter Kim Jong Hyo kei1000@infostock.com
